BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25600474)

  • 1. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
    Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
    Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
    Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
    J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
    Moriwaki K; Fukuda H
    Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term persistence with anti-osteoporosis drugs after fracture.
    Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
    Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
    Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
    Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid-induced osteoporosis management among seniors, by year, sex, and indication, 1996-2012.
    Albaum JM; Lévesque LE; Gershon AS; Liu G; Cadarette SM
    Osteoporos Int; 2015 Dec; 26(12):2845-52. PubMed ID: 26138581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
    Liu J; Guo H; Rai P; Pinto L; Barron R
    Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
    Jacob L; Dreher M; Kostev K; Hadji P
    Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway.
    Apalset EM; Lunde A; Hoff M; Ehrenstein V; Tell GS
    Arch Osteoporos; 2020 Aug; 15(1):121. PubMed ID: 32757143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness of a Private Orthopaedic Practice-Based Osteoporosis Management Service to Reduce the Risk of Subsequent Fractures.
    Sietsema DL; Araujo AB; Wang L; Boytsov NN; Pandya SA; Haynes VS; Faries DE; Taylor KA; Baser O; Jones CB
    J Bone Joint Surg Am; 2018 Nov; 100(21):1819-1828. PubMed ID: 30399076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.
    Yu SF; Chen JF; Chen YC; Lai HM; Ko CH; Chiu WC; Su FM; Hsu CY; Su BY; Wu CH; Cheng TT
    Medicine (Baltimore); 2017 Feb; 96(5):e5959. PubMed ID: 28151883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
    Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.